🧬The Latest Life Science Innovations Changing Patients Lives | October 28, 2026

Innovations and Impacts

🧬The Latest Life Science Innovations Changing Patients Lives | October 28, 2026

October 28, 2026

The California Biotechnology Foundation is committed to keeping you up to date about the latest breakthroughs in life science treatments and the impact of one of California’s largest industries in the state and beyond. This newsletter edition, as of October 28, 2026, brings you updates directly from the forefront of healthcare and medical innovation. Among the notable advancements featured are:

  • The FDA approved GSK’s Hibsago, the first treatment of its kind for chronic hepatitis B, which helped one in five clinical trial patients achieve a functional cure when combined with standard antiviral therapy.
  • Chico-based Enloe Health received a $9 million grant from the California Institute for Regenerative Medicine to build a Northern California hub for cell and gene therapies, bringing advanced treatments and clinical trials for cancer, autoimmune diseases and rare genetic disorders closer to patients.
  • The FDA expanded approval of Novartis’ Rhapsido, making it the first treatment for symptomatic dermographism, a form of chronic hives triggered by scratching or friction.

Recent News

  • GSK brings promise of ‘functional cure’ to hepatitis B finish line with FDA nod for Hibsago
    Fierce Pharma – October 21, 2026
    With the FDA’s green light in hepatitis B, GSK and its Ionis-licensed medicine bepirovirsen have racked up several notable distinctions, bringing the antisense oligonucleotide class to bear against the virus for the first time alongside the promise of functional cure-standard efficacy versus pre-existing treatments. Late Tuesday, the FDA gave the go-ahead to bepirovirsen to treat chronic hepatitis B (CHB) virus infection in tandem with nucleos(t)ide analogue reverse transcriptase inhibitor (Nrtl) therapy in adults without cirrhosis. The drug will now carry the commercial moniker Hibsago and is specifically indicated in those who’ve already been taking Nrtl therapy for at least six months, and who have suppressed hepatitis B virus DNA and virus surface antigen levels no greater than 3000 IU/ml.
  • Gilead ‘sitting on a foundational asset’ after oral UC drug’s phase 2 win
    Fierce Biotech – October 19, 2026
    Gilead Sciences has notched a phase 2 win in ulcerative colitis (UC), with its once-daily pill emvistegrast outperforming placebo on the study’s primary endpoint and setting the stage for a late-stage trial in 2027. At week 12, 66% of patients receiving the 200-mg dose of emvistegrast achieved a clinical response, compared with 37% of placebo recipients, according to an Oct. 19 release. Clinical remission was achieved by 31% of patients in the treatment group, versus 8% in the placebo group. The results came from the ongoing phase 2 Swift trial, which enrolled 238 adults with moderately to severely active UC. The randomized, placebo-controlled study evaluated three doses of emvistegrast: 25 mg, 75 mg and 200 mg—and the findings were presented at United European Gastroenterology Week 2026 in Barcelona, Spain.
  • Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
    BioPharma Dive – October 14, 2026
    After years of research, the first disease-modifying drugs in decades for Alzheimer’s won approval in the early 2020s in the form of Aduhelm, Leqembi and Kisunla. These medicines address one of the main biological signs of Alzheimer’s, the buildup of toxic clumps of a protein called amyloid beta in patients’ brains. Leqembi and Kisunla have notable limitations, however, such as a safety warning not to prescribe them in people taking commonly used blood thinners. Moreover, their benefits are modest. Kisunla, for example, removed nearly all the amyloid lesions in the brains of most of the enrollees in a Phase 3 trial, but didn’t stop, let alone reverse disease progression. The accumulation of tau is also believed to be implicated in disease progression, making the protein another popular target among drugmakers. Multiple would-be medicines have struggled to show a clear benefit, though research remains ongoing.
  • Enloe Health awarded $9M grant to expand access to cell and gene therapies
    ABC7 – October 13, 2026
    Patients in Northern California who have had to travel hours for advanced cancer treatments and other specialty treatments could soon have options closer to home. Enloe Health in Chico has been awarded a $9 million grant to expand access to specialized cell and gene therapies in Northern California. The funding could bring advanced treatments and clinical trials to patients who otherwise would need to travel to major medical centers. The grant from the California Institute for Regenerative Medicine will fund the development of a Northern California Community Care Center of Excellence, a regional hub for regenerative medicine, specialized care and clinical research. Enloe will work with UC Davis and Healthy Rural California to establish the program, which is expected to begin in February 2027.
  • FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
    U.S. Food and Drug Administration – October 8, 2026
    On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
  • US FDA expands use of Novartis drug for chronic skin condition
    Reuters – October 7, 2026
    The US Food and Drug Administration has expanded the use of Novartis’ drug to treat adults with ​a chronic skin condition that causes recurring itchy welts, ‌the Swiss drugmaker said on Wednesday. The condition, called symptomatic dermographism, is a form of chronic hives in which scratching, rubbing or ​friction on the skin can trigger itchy welts. The ​approval adds to momentum for the drug, remibrutinib, which investors ⁠have increasingly focused on after recent late-stage failures of the ​company’s cholesterol drug pelacarsen and muscle-wasting disease therapy del-desiran ​increased scrutiny of its pipeline.
  • Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
    Pfizer – October 7, 2026
    Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.
  • Cerevance rescues its Parkinson’s drug with phase 3 win
    Fierce Biotech – October 7, 2026
    Cerevance’s oral non-dopaminergic therapy has redeemed itself by improving both motor and non-motor symptoms in a phase 3 Parkinson’s disease study. The win came over a year after the non-dopaminergic therapy missed its primary endpoint in a phase 2 monotherapy study. The GPR6 inverse agonist, called solengepras, significantly reduced OFF time, a term for the period when medication wears off and symptoms return or worsen between doses. Based on the findings, the Boston biotech plans to seek FDA approval of solengepras for Parkinson’s disease, according to an Oct 7. release. The phase 3 trial enrolled 341 participants to receive either 150 mg or 75 mg doses of solengepras, or placebo, orally once daily for 12 weeks as an adjunctive treatment to levodopa in Parkinson’s patients experiencing motor fluctuations.
  • Nobel medicine prize goes to 3 scientists for shining light on brain activity
    AP News – October 5, 2026
    The Nobel Prize in medicine was awarded Monday to three scientists whose work led to a tool that uses light to help unravel how the brain works. Dr. Karl Deisseroth, Peter Hegemann and Georg Nagel carried out research that opened a new field with the wonky name optogenetics, combining light with genes to switch on and off neurons in living brains. Separate research from the trio — one of whom lives in the U.S. and two in Germany — resulted in a technique that helps to identify neural pathways responsible for behavior and disease. It could lead to treatments, such as restoring some vision in people with a genetic form of blindness. Experts said the advancements greatly expanded the understanding of how the brain is organized.
  • Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
    BioPharma Dive – October 5, 2026
    Vaxcyte’s study results were among the most eagerly anticipated readouts remaining this year. Salim Syed, an analyst with the firm Mizuho Securities, referred to them in June as a “‘must-play’ catalyst for biotech investors.” The reason for the intense interest is that Vaxcyte’s shot is the most advanced challenger to a vaccine business that generates billions of dollars each year. Led by Pfizer’s dominant Prevnar franchise, these vaccines prevent pneumococcal diseases that can cause a variety of health problems, from mild sinus issues to life-threatening pneumonia and meningitis. Pfizer’s business is largely built on a 13-strain shot that emerged in 2010 and has since expanded to include a 20-strain alternative. And while others such as Merck and GSK have invested heavily in their own competitors, Pfizer’s grip has held firm, with its franchise earning more than $6 billion last year.
  • With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL
    Fierce Pharma – October 2, 2026
    Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Friday’s approval follows Jaypirca’s FDA approval in 2023 as a third-line therapy for CLL/SLL and a follow-on go-ahead in the second-line setting, making it the fourth BTK inhibitor cleared for previously untreated CLL/SLL. Before Friday’s FDA green light, Jaypirca had already secured market authorization in the European Union across all lines of therapy. “This milestone underscores Jaypirca’s versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca’s broad applicability as a meaningful treatment option for people with CLL or SLL,” Jacob Van Naarden, executive vice president and president of Lilly Oncology, said in a statement.

Stay informed on the latest news and trends on the economic and health benefits of this industry by visiting the new CABiotech.org.

If you have any questions about hosting informational briefings for your colleagues serving in the legislature, contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or [email protected].